Antenatal maternal serum profiles.
Since the late 1970s antenatal biochemical screening for pregnancies associated with neural tube defects has become a routine part of obstetric practice in the UK. More recently, biochemical screening programmes for chromosomal anomalies such as trisomy 21 (Down's syndrome) and trisomy 18 (Edward's syndrome) have moved on from the research stage and have begun to be implemented.
Spencer
K
K
Clinical Biochemistry Department, Oldchurch Hospital, Romford, Essex.
D014408:Biomarkers, Tumor / Q000097:blood; D006063:Chorionic Gonadotropin / Q000097:blood; D018997:Chorionic Gonadotropin, beta Subunit, Human; D002869:Chromosome Aberrations / Q000097:blood / Q000517:prevention & control*; D025063:Chromosome Disorders; D005260:Female; D006801:Humans; D015994:Incidence; D008403:Mass Screening / Q000009:adverse effects / Q000379:methods*; D008423:Maternal Age; D009436:Neural Tube Defects / Q000097:blood / Q000517:prevention & control*; D010446:Peptide Fragments / Q000097:blood; D011247:Pregnancy; D018566:Pregnancy, High-Risk; D011296:Prenatal Diagnosis / Q000009:adverse effects / Q000379:methods*; D012307:Risk Factors; D012680:Sensitivity and Specificity; D000509:alpha-Fetoproteins / Q000032:analysis
D014408:Biomarkers, Tumor; D006063:Chorionic Gonadotropin; D018997:Chorionic Gonadotropin, beta Subunit, Human; D010446:Peptide Fragments; D000509:alpha-Fetoproteins